Cyber PMS Adopted for IQVIA Japan Group's One-Stop Post-Marketing Surveillance Solution
New Medical Real World Data Research Organization, Inc. (PRiME-R) and IQVIA Japan Group are strengthening their collaboration in post-marketing surveillance (PMS). PRiME-R's Cyber PMS has been adopted for IQVIA's one-stop solution, providing efficient and high-quality PMS support services utilizing Real World Data (RWD).
📋 Article Processing Timeline
- 📰 Published: May 13, 2026 at 22:00
- 🔍 Collected: May 13, 2026 at 13:31
- 🤖 AI Analyzed: May 13, 2026 at 13:52 (20 min after Collected)
New Medical Real World Data Research Organization, Inc. (Headquarters: Kyoto City, Representative Director and President: Koji Korekawa, hereinafter 'PRiME-R'), following its collaboration*1 in clinical research with IQVIA Services Japan LLC (Location: Minato-ku, Tokyo, President: Fumihiko Ugajin, hereinafter IQVIA) of the IQVIA Japan Group, will begin providing integrated support services for post-marketing surveillance (hereinafter 'PMS') as well.
*1 Cyber Oncology® adopted for IQVIA Japan Group's one-stop solution for clinical research https://prime-r.inc/newsrelease/734/
1. Background of the Initiative
In recent years, as the need for PMS utilizing Real World Data (RWD) has increased, both medical institutions and pharmaceutical companies are seeking efficient and high-quality PMS implementation.
PRiME-R began providing cancer-related PMS support services using Cyber PMS, based on Cyber Oncology®, in June 2025, as a service that reduces the data entry burden on medical institutions and enables high-quality data collection.
This collaboration will combine IQVIA's extensive PMS experience and know-how with PRiME-R's RWD platform to establish a system that consistently supports PMS from planning to implementation and reporting.
*Regarding the start of PMS support services https://prime-r.inc/newsrelease/893/
2. Overview and Features of this Solution
■ Reduced Burden on Medical Sites and Improved Data Quality
Cyber PMS can be launched and linked from electronic medical record terminals. It is equipped with functions such as audit trails, electronic signatures, and account management, compliant with ER/ES guidelines*2. As it allows for more efficient PMS implementation compared to EDC, it reduces the burden on medical institutions while achieving high-quality data collection.
*2 PMS must be implemented based on the "Ordinance on Standards for Conducting Post-Marketing Surveillance and Tests of Pharmaceuticals" (Ministry of Health, Labour and Welfare Ordinance No. 171 of December 20, 2004) (GPSP Ordinance). When using a system, it must comply with the "Guidelines on the Use of Electronic Records and Electronic Signatures in Applications for Approval or Permission of Pharmaceuticals, etc." (Yakushokuhatsu No. 0401022 of April 1, 2005) (ER/ES Guidelines).
■ Provision of One-Stop PMS Support Services
By integrating PRiME-R's developed Cyber PMS with IQVIA's long-standing PMS experience and know-how, the solution supports the product lifecycle from survey planning to re-examination application.
■ Establishment of an Implementation Foundation as an IQVIA Qualified Vendor, anticipating practical operations
PRiME-R has been confirmed as an IQVIA Qualified Vendor regarding its quality control system and the establishment of related SOPs. This means that for pharmaceutical companies, a system anticipating post-introduction operations is already in place, contributing to the smooth contract and setup processes.
3. Future Developments
This collaboration aims not only to provide a system but also to comprehensively resolve various issues arising in PMS implementation, including reducing the burden on medical institutions and operational challenges.
PRiME-R will continue to promote the utilization of RWD through clinical research support using Cyber Oncology® and PMS implementation support services using Cyber PMS, striving for the development of next-generation medicine. We kindly ask for your continued support.
*1 Cyber Oncology® adopted for IQVIA Japan Group's one-stop solution for clinical research https://prime-r.inc/newsrelease/734/
1. Background of the Initiative
In recent years, as the need for PMS utilizing Real World Data (RWD) has increased, both medical institutions and pharmaceutical companies are seeking efficient and high-quality PMS implementation.
PRiME-R began providing cancer-related PMS support services using Cyber PMS, based on Cyber Oncology®, in June 2025, as a service that reduces the data entry burden on medical institutions and enables high-quality data collection.
This collaboration will combine IQVIA's extensive PMS experience and know-how with PRiME-R's RWD platform to establish a system that consistently supports PMS from planning to implementation and reporting.
*Regarding the start of PMS support services https://prime-r.inc/newsrelease/893/
2. Overview and Features of this Solution
■ Reduced Burden on Medical Sites and Improved Data Quality
Cyber PMS can be launched and linked from electronic medical record terminals. It is equipped with functions such as audit trails, electronic signatures, and account management, compliant with ER/ES guidelines*2. As it allows for more efficient PMS implementation compared to EDC, it reduces the burden on medical institutions while achieving high-quality data collection.
*2 PMS must be implemented based on the "Ordinance on Standards for Conducting Post-Marketing Surveillance and Tests of Pharmaceuticals" (Ministry of Health, Labour and Welfare Ordinance No. 171 of December 20, 2004) (GPSP Ordinance). When using a system, it must comply with the "Guidelines on the Use of Electronic Records and Electronic Signatures in Applications for Approval or Permission of Pharmaceuticals, etc." (Yakushokuhatsu No. 0401022 of April 1, 2005) (ER/ES Guidelines).
■ Provision of One-Stop PMS Support Services
By integrating PRiME-R's developed Cyber PMS with IQVIA's long-standing PMS experience and know-how, the solution supports the product lifecycle from survey planning to re-examination application.
■ Establishment of an Implementation Foundation as an IQVIA Qualified Vendor, anticipating practical operations
PRiME-R has been confirmed as an IQVIA Qualified Vendor regarding its quality control system and the establishment of related SOPs. This means that for pharmaceutical companies, a system anticipating post-introduction operations is already in place, contributing to the smooth contract and setup processes.
3. Future Developments
This collaboration aims not only to provide a system but also to comprehensively resolve various issues arising in PMS implementation, including reducing the burden on medical institutions and operational challenges.
PRiME-R will continue to promote the utilization of RWD through clinical research support using Cyber Oncology® and PMS implementation support services using Cyber PMS, striving for the development of next-generation medicine. We kindly ask for your continued support.